Importantly, this trial also enrolled patients based on the overexpression of protein kinase C-iota (PKC-ι), an oncogenic kinase implicated in tumor progression and poor clinical outcomes across multiple cancer types. This evidence concerns the gene PRKCI and neoplasm.